The present invention relates to a method for the diagnosis, prognosis, risk assessment, risk stratification, monitoring, therapy guidance and/or therapy control of a fungal infection, in particular invasive fungal infections (IFI) and/or the ruling in or ruling out of an fungal infection and/or the differential diagnosis of a fungal colonization vs. an invasive fungal infection in a subject, wherein in particular the subject has an increased risk of getting or having a fungal infection and/or the subject is in a critical disease state, particularly has an existing infection and/or a state of sepsis, particularly a septic shock. The method of the invention comprises determining the level of at least one marker selected from the group of ICAM1, AHSG, CPN1, FABP1, HRG, PIGR, RAP1A, THBS1, VCL, ET-1. Furthermore, the invention relates to a diagnostic assay and a kit for carrying out the method.

The present invention relates to biomarkers and methods of using the same. Specifically, the present invention relates to biomarkers for nonalcoholic fatty liver disease and related disease phenotypes and methods of using the same.

Provided are methods for quantitating an amount of a polypeptide that comprises a portion of an antibody present in a sample (e.g., a plasma or serum sample) wherein the antibody comprises a constant region (e.g., a heavy chain or light chain constant region) that comprises an engineered mutation.

The present invention relates to a system for analysing the composition of a quenched flow reaction liquid comprising a quenched flow reactor, and a high performance liquid chromatography (HPLC) apparatus; wherein the quenched flow reactor is in fluid communication with the HPLC apparatus.

Disclosed are oral wash compositions for collection of analyte in oral fluid sample. The oral wash includes an internal tracer, which can be directly detected by a mass-spec-based analytical method such as LC-MS, GC-MS, CE-MS, HPLC-MS/MS, HPLC-TOF or MALDI-TOF assay, along with all the other analytes being tested in the collected oral fluid. The oral wash optionally includes agents to induce salivation, maintain oral wash integrity at room temperature, and stabilize the collected oral fluid, and one or more dyes. The oral wash is used to collect saliva from the oral cavity, in order to determine the presence of an analyte in the saliva. The method includes rinsing the oral cavity with the oral wash for a period of time effective to stimulate saliva production, collecting the resulting fluid and subjecting the resulting fluid to a mass-spec-based analytical method to detect the presence of an analyte in the sample.

The present disclosure provides compositions and methods involving the use of mucin-specific proteases for mucin-specific cleavage, labeling, and/or enrichment of mucin domain glycoproteins. Also provided are methods for the analysis of mucin-domain glycoproteins useful in glycomapping of mucin glycosites and their associated glycoforms. Provided compositions and methods are also useful for selective cleavage, release, and enrichment of mucins from cell and tissue samples, for the study of native mucin biology, and for the detection and analysis of mucins that are aberrantly expressed in various conditions, including cancer.

The present invention provides methods and systems for the rapid determination of the intact mass of non-covalently associated antibody heavy chains (HC) and light chains (LC) which result from the attachment of drug conjugates to interchain cysteine residues. By analyzing the antibody-drug conjugate (ADC) using native desalting conditions, the intact-bivalent structure of the ADC, which ordinarily would decompose as a consequence of denaturing chromatographic conditions typically used for LCMS, is maintained. The mass of the desalted ADC is subsequently determined using desolvation and ionization ESI-MS conditions. The methods described herein provide for direct measurement of the intact mass of an ADC conjugated at interchain cysteine residues. The methods described herein also provide for the relative quantitation of the individual ADC species.

In some embodiments, a mass spectrometry tag may comprise a linker region, a mass balance region, and a reporter region. The mass spectrometry tag may be configured to fragment in a mass spectrometer via an energy dependent process to produce multiple reporter molecules. For example, the reporter region of the tag may be configured to produce at least two reporter molecules via fragmentation. In some embodiments, one or more regions of the tag may comprise at least one heavy isotope. In some such embodiments, the ability to fragment into multiple reporter molecules as well as the placement and/or number of heavy isotope(s) allows the mass spectrometry tag to be distinguished from other similar mass spectrometry tags. In some such embodiments, the ability to distinguish between tags having the same or substantially similar total mass to charge ratio and reporter region mass may allow the system to have a greater multiplexing capacity than conventional systems.

[OBJECT] To enable accurate identification of a specific serotype of Salmonella bacteria in a method for analyzing a microorganism using a MALDI-MS.

[MEANS FOR SOLVING PROBLEM] The present invention is a method for analyzing a microorganism including an identification step for determining which of Abony and Pakistan which are two serotypes of Salmonella bacteria is contained in a sample which contains either Abony or Pakistan, based on the presence or absence of a peak (or peaks) at a predetermined mass-to-charge ratio (or ratios) in a mass spectrum obtained by a mass spectrometric analysis of the sample, or a method for analyzing a microorganism including an identification step for determining which of Minnesota. Infantis and Brandenburg which are three serotypes of Salmonella bacteria is contained in a sample which contains Minnesota. Infantis or Brandenburg, based on the presence or absence of a peak (or peaks) at a predetermined mass-to-charge ratio (or ratios) in a mass spectrum obtained by a mass spectrometric analysis of the sample, or a method for analyzing a microorganism including an identification step for determining which of Schwarzengrund and Montevideo which are two serotypes of Salmonella bacteria is contained in a sample which contains either Schwarzengrund or Montevideo, based on the presence or absence of a peak (or peaks) at a predetermined mass-to-charge ratio (or ratios) in a mass spectrum obtained by a mass spectrometric analysis of the sample.

To provide a biomarker which is a metabolite included in a biological sample, and which can be collected in a noninvasive method and detected in a convenient analysis method, and which varies according to progression of pathological conditions of irritable bowel syndrome (IBS). Furthermore, such biomarkers are useful for determination of the presence or absence of morbidity of IBS, determination of severity of IBS, determination of types of IBS, determination of necessity of treatment of IBS, and confirmation of drug efficacy of an IBS therapeutic agent.